prabhavathi fernandes ph d president and ceo cempra pharmaceuticals inc prabha@fernandes domain com
Download
Skip this Video
Download Presentation
Prabhavathi Fernandes, Ph.D. President and CEO Cempra Pharmaceuticals, Inc. [email protected]

Loading in 2 Seconds...

play fullscreen
1 / 8

Joint Meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee - PowerPoint PPT Presentation


  • 1347 Views
  • Uploaded on

Joint Meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee Open Public Meeting December 14-15, 2006. Prabhavathi Fernandes, Ph.D. President and CEO Cempra Pharmaceuticals, Inc. [email protected]

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Joint Meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee' - Mia_John


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
prabhavathi fernandes ph d president and ceo cempra pharmaceuticals inc prabha@fernandes domain com

Joint Meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Advisory CommitteeOpen Public MeetingDecember 14-15, 2006

Prabhavathi Fernandes, Ph.D.

President and CEO

Cempra Pharmaceuticals, Inc.

[email protected]

all of us have the same goals
All of Us Have the Same Goals

We all want

affordable antibiotics -that are safe and

effective against resistant bacteria

Patients

Physicians

Pharma &

Biotech

FDA

Success REQUIRES that we are all on the same tablet !

the tablet is broken
The Tablet is Broken

Lack of clear guidelines to develop antibacterials makes the financial risk too high

Pharma & Biotech

The return on investment is too low

Patients

There are not enough safe and effective antibiotics

FDA

We need extraordinarily safe antibiotics that are more effective than placebo

Physicians

using ketek as an example find the cause of the problem
Using Ketek as an Example - Find the Cause of the Problem

Antibiotics developed & used for serious infections

Antibiotics safe

& effective

Patients demand for antibiotics for simple “infections”

Pharma Success

1975

1940

FDA, patients & Congress

question use and safety of antibiotics

Physician & Patient comfort

WHERE ARE THE MAGIC BULLETS?

Increased profits from antibiotic sales for simple infections

2005

1985

Millions of

patients exposed

Increased patient exposure –increased reporting of adverse effects

Risk-Benefit?

Patient demand and

pharma greed for

drugs for simple infections

Pharma markets aggressively for simple infections

thoughts that have arisen after ketek was approved
Thoughts that Have Arisen After Ketek was Approved
  • Should wide-spread use be discouraged to prevent selection of resistant bacteria?
    • We are killing the goose that is laying the golden eggs
  • Should FDA protect public from unnecessary exposure to antibiotics that can result in harm?
  • Should patients be using so many antibiotics for simple infections?
  • Should physicians be writing so many antibiotic prescriptions?
  • Should pharma sales reps promote antibiotics for simple infections?
unrealistic expectations
Unrealistic Expectations
  • No drug (or antibiotic) is completely safe
    • Risk-benefit analysis is easier when treating serious infections
  • It is impossible to detect every rare side effect in any-size trials- no point in increasing the clinical trial size
    • Need pre-clinical toxicology, clinical safety in 1000 patients
    • Need mandatory submission of Phase IV data
    • Ban on promotion for simple infections
  • Waiting to get sufficient patients with resistant bacterial infections to prove efficacy in clinical trials is like waiting until a house is on fire to buy insurance!
proposal for clinical trial design to demonstrate efficacy
Proposal for Clinical Trial Design to Demonstrate Efficacy
  • For simple infections, placebo controlled trials are the only way to demonstrate that a drug is effective
  • Comparator controlled trials should be used for serious or complicated infections to demonstrate efficacy
    • 200 cases tested with new drug vs. one of the TOP two standard-of-care antibiotics
    • Non inferiority to these compounds should be approved
    • Approval for “organ system” of infection (e.g. Respiratory, SSSI)
  • In infectious diseases, the biomarker is isolation of the pathogen – demonstrate the pathogen and clearance
  • A new antibiotic that has activity in vitro and in animal model against resistant bacteria, and has equal or even less activity as comparator antibiotics in clinical trials, should be approved for treating resistant bacteria
encouragement for developing new antibiotics
Encouragement for Developing New Antibiotics
  • Clear FDA guidelines to make drug development feasible
    • Two adequate (400 patients each) and comparator controlled, non-inferiority studies for serious infections
    • Approval on the ORGAN SYSTEM basis to decrease costs of multiple clinical trials
    • Some diseases are rare (e.g. endocarditis) and guidelines could combine many rare, deep tissue/organ infections into one claim
  • Government should provide incentives to small companies who are addressing public health needs for new antibiotics – eg. matching grants, development expense refunds, tax incentives etc.
ad